A settlement worth more than $200 million for victims of a deadly fungal meningitis outbreak tied to tainted steroid drugs is being distributed, even as other defendants fight claims in continuing multidistrict litigation. Drugs from the now defunct New England Compounding Center (NECC) have been linked to 64 deaths and 751 injuries.
The company’s Chapter 11 bankruptcy plan approving the payouts became final earlier this month, following U.S. Bankruptcy Judge Henry J. Boroff’s confirmation in May. The estimated $211 million settlement includes $21.8 million in potential tax refunds due to New England Compounding shareholders.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
